次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

前立腺がん治療(薬および医療機器)の世界市場2014-2024年

THE PROSTATE CANCER THERAPEUTICS MARKET FORECAST 2014-2024
Opportunities for Leading Companies

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年7月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文208ページになります。
商品コード:VGN252

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】VGN252_Prostate_Cancer_2024thumbnail.jpgレポート表紙
当レポートでは、前立腺がん治療の世界市場は2014年に70億ドルに達し、2024年にかけて堅実な市場成長が続くと予測しています。前立腺がん治療薬や療法(デバイス)への需要増加、医療保険適用の拡充、新たな診断法の成功などは、この市場拡大に寄与する要因と見込まれます。成熟市場国と新興市場国、ともに拡大基調ですが、インド、ブラジル、中国、メキシコは特に高い成長が続くと予想されます。
当レポートは、同市場の2024年に至る市場予測、詳細なセグメント別予測分析に加え、市場動向、研究開発動向、リーディング企業情報などを概略以下の構成でお届けいたします。

【レポート構成概要】
・前立腺がん治療(薬、医療機器)の世界市場予測2014-2024年
・全208ページ、160個のデータ表、グラフ類で分析数値化
・成長率、市場シェア、市場の促進要因と阻害要因
・業界専門家オピニオンインタビュー:
- Professor Malcolm Mason, Cancer Research UK
- Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
- Dr. Estuardo Aguilar-Cordova, Co-Founder, CEO and Chairman, Advantagene

・セグメント別市場予測2014-2024年
• 前立腺がん治療薬Prostate cancer drugs
• 前立腺がん治療機器Prostate cancer devices

・治療薬主要9製品、製品別売上予測~2024年
• Zytiga
• Lupron
• Xtandi
• Zoladex
• Casodex
• Jevtana
• Provenge
• Taxotere
• Xofigo

・治療機器、セグメント別市場予測2014-2024年
• 近接照射療法
• 根治的前立腺切除術
• 外照射療法
• 凍結療法
• HIFU(高密度焦点式超音波治療法)

・主要13ヶ国、国別市場予測~2024年
• 米国
• 日本
• ドイツ
• フランス
• 英国
• イタリア
• スペイン
• その他欧州
• ブラジル
• ロシア
• インド
• 中国
• 韓国
• メキシコ
• その他Rest of the World

・リーディング企業7社プロフィール。業績、展望、新製品、提携、合弁など
• Johnson and Johnson
• AstraZeneca
• Sanofi
• AbbVie
• Varian Medical Systems
• Elekta
• Theragenics Corporation (Juniper)

・市場動向
• 市場成長に寄与するmCRPC向け医薬品
• 強力な新薬開発パイプライン
• 高い成長を見せるロボット前立腺切除
• 人口高齢化に促進される前立腺がん治療市場
• 世界的な拡大傾向、新興国への進出
• 幹細胞
• 激しい企業間競合

Visiongain is a trading partner with the US Federal Government
【レポート詳細目次は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

THE PROSTATE CANCER THERAPEUTICS MARKET FORECAST 2014-2024
Opportunities for Leading Companies

Table of Contents

1. Report Overview

1.1 The Prostate Cancer Therapeutics Market Overview
1.2 Prostate Cancer Therapeutics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Introduction to Prostate Cancer

2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Apoptosis Pathways
2.2.3 Lack Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors for Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
2.8.3 Prostate Cancer Screening: Beneficial or Costly?
2.8.4 Newly Approved Tests May Improve Diagnosis
2.8.4.1 Prostate Cancer Diagnostics in the Pipeline
2.9 Treatment Sequence for Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010

3. The Prostate Cancer Therapeutics Market 2014-2024

3.1 The Global Prostate Cancer Therapeutics Market, 2013
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2014-2024
3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2014-2024

4. The Prostate Cancer Drugs Market 2014-2024

4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher Competition
4.2 The Prostate Cancer Drugs Market, 2013
4.3 Leading Prostate Cancer Drugs: Market Forecast, 2014-2024
4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2014-2024
4.4 First Generation Chemotherapies
4.4.1 Taxotere (Sanofi)
4.4.1.1 Taxotere Sales, 2013
4.4.1.2 Taxotere Sales Forecast, 2014-2024
4.5 Second Generation Chemotherapies
4.5.1 Jevtana (Sanofi)
4.5.1.1 Jevtana Sales, 2013
4.5.1.2 Jevtana Sales Forecast, 2014-2024
4.6 First Generation Hormones
4.6.1 Casodex (AstraZeneca)
4.6.1.1 Casodex Sales, 2013
4.6.1.2 Casodex Sales Forecast, 2014-2024
4.6.2 Lupron (AbbVie)
4.6.2.1 Lupron Sales, 2013
4.6.2.2 Lupron Sales Forecast, 2014-2024
4.6.3 Zoladex (AstraZeneca)
4.6.3.1 Zoladex Sales, 2013
4.6.3.2 Zoladex Sales Forecast, 2014-2024
4.7 Second Generation Hormones
4.7.1 Zytiga (Johnson & Johnson)
4.7.1.1 Zytiga Sales, 2013
4.7.1.2 Zytiga Sales Forecast, 2014-2024
4.7.2 Xtandi (Medivation/ Astellas Pharma)
4.7.2.1 Xtandi Sales, 2013
4.7.2.2 Xtandi Sales Forecast, 2014-2024
4.8 Immunotherapies
4.8.1 Provenge (Dendreon Corporation)
4.8.1.1 Provenge Sales, 2013
4.8.1.2 Provenge Sales Forecasts, 2014-2024
4.9 Radiopharmaceuticals
4.9.1 Xofigo (Bayer)
4.9.1.1 Xofigo Sales, 2013
4.9.1.2 Xofigo Sales Forecast, 2014-2024
4.10 Other Drugs
4.11 Prostate Cancer Drugs Pipeline, 2014
4.11.1 Phase III Development
4.11.1.1 DCVax-Prostate (NorthWest Biotherapeutics)
4.11.1.2 Tookad Soluble (Steba Biotech)
4.11.1.3 ProstAtak (Advantagene)
4.11.1.4 Tasquinimod (Active biotech AB/Ipsen)
4.11.1.5 Custirsen (Oncogenex/ Teva)
4.11.1.6 Cabozantinib (Exelixis)
4.11.1.7 Prostvac (Bavarian Nordic)
4.11.2 Failed Phase III Drugs
4.11.2.1 Custirsen (OncoGenex)
4.11.2.2 Yervoy (Bristol Myers Squibb)
4.11.2.3 Orteronel (Millenium Pharmaceuticals)
4.11.3 Phase II development
4.11.3.1 GDC-0980 (Roche)
4.11.3.2 GDC-0068 (Roche)
4.11.3.3 PSMA ADC (Progenics Pharmaceuticals)
4.11.3.4 Galeterone (Tokai Pharmaceuticals)
4.11.3.5 OGX-427 (OncoGenex Pharmaceuticals)
4.11.3.6 ARN-509 (Johnson & Johnson)
4.11.3.7 Abituzumab (Dl7E6) (Merck)
4.11.3.8 Ipilimumab (Yervoy) (Bristol Myers Squibb)
4.11.4 Phase I
4.11.4.1 ASG-5ME (Agensys/Seattle Genetics)
4.11.4.2 EMD-525797 (EMD Serono)
4.11.4.3 MGAH22 (MacroGenics)
4.11.4.4 RG7450 (Roche)
4.11.4.5 BAY2010112 (Bayer Pharmaceuticals)
4.11.4.6 BX-201 (Bellicum Pharmaceuticals)
4.12 The Leading Companies in the Prostate Cancer Drugs Market, 2014
4.12.1 Johnson & Johnson (J&J)
4.12.1.1 Sales and Performance Analysis, 2013
4.12.1.2 Pharmaceutical Segment Sales Analysis, 2013
4.12.1.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.1.4 Pharmaceutical Segment R&D Performance Analysis, 2013
4.12.1.5 Recent M&A Activity
4.12.1.5.1 Acquisition of Aragon Pharmaceuticals
4.12.2 AstraZeneca
4.12.2.1 Sales and Performance Analysis, 2013
4.12.2.2 Pharmaceutical Segment Sales Analysis by Segment, 2013
4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.2.4 R&D Performance Analysis, 2013
4.12.3 Sanofi
4.12.3.1 Sales and Performance Analysis, 2013
4.12.3.2 Sales and Performance Analysis by Segment, 2012
4.12.3.3 Oncology Sales and Performance Analysis, 2013
4.12.3.4 R&D Performance Analysis, 2013
4.12.3.5 Oncology Pipeline Portfolio
4.12.4 AbbVie
4.12.4.1 Sales and Performance Analysis, 2013
4.12.4.2 R&D Performance Analysis, 2013
4.12.4.3 Oncology Portfolio Pipeline Products, 2013

5. The Prostate Cancer Devices Market 2014-2024

5.1 The Prostate Cancer Devices Market 2013
5.2 The Prostate Cancer Devices Market Forecast, 2014-2024
5.2.1 The Market Shares of Leading Prostate Cancer Devices Submarkets, 2014-2024
5.3 The Brachytherapy Market, 2014-2024
5.4 The Radical Prostatectomy Market 2014-2024
5.4.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth
5.5 The External Beam Radiation Therapy Market, 2014-2024
5.6 The HIFU Market, 2014-2024
5.7 The Cryotherapy Market, 2014-2024
5.8 Leading Companies in the Prostate Cancer Devices Market 2014-2024
5.8.1 Varian Medical Systems
5.8.1.1 Sales and Performance Analysis, 2013
5.8.1.2 Oncology Segment Sales Analysis, 2013
5.8.1.3 Sales Analysis by Region, 2013
5.8.1.4 R&D Performance Analysis, 2013
5.8.1.5 Key Oncology Products, 2013
5.8.1.6 Varian and Siemens Partnership: Shaping the Future of Cancer Care
5.8.2 Elekta
5.8.2.1 Sales and Performance Analysis, 2013
5.8.2.2 Sales and Performance Analysis by Region, 2012
5.8.2.3 Elekta and Philips Establish Research Consortium
5.8.2.4 Product Launch and Development, 2013
5.8.3 Theragenics Corporation (acquired by Juniper)
5.8.3.1 Theragenics Sales Performance Analysis, 2012
5.8.3.2 Theragenics Sales Performance by Operation, 2012
5.8.3.3 Theragenics sales and Performance Analysis by Business Unit, 2012
5.8.3.4 Mergers and Acquisitions
5.8.3.4.1 Juniper’s acquisition of Theragenics
5.8.3.4.2 Acquisition of Needle Tech Products
5.8.3.4.3 Acquisition of Galt Medical
5.8.3.4.4 Acquisition of CP Medical

6. The Leading National Markets 2014-2024

6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2013
6.2 The Prostate Cancer Therapeutics Market: Regional Forecast, 2014-2024
6.2.1 Market Shares Forecasts of Leading National Prostate Cancer Therapeutics
Markets, 2014-2024
6.3 The US Prostate Cancer Therapeutics Market 2014-2024: Largest National Market
6.4 The European Prostate Cancer Therapeutics Market, 2013
6.4.1 The European Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.1 The German Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.2 The French Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.3 The UK Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.4 The Spanish Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.5 The Italian Prostate Cancer Therapeutics Market, 2014-2024
6.5 The Japanese Prostate Cancer Therapeutics Market, 2014-2024
6.6 The Brazilian Prostate Cancer Therapeutics Market, 2014-2024
6.7 The Russian Prostate Cancer Therapeutics Market, 2014-2024
6.8 The Indian Prostate Cancer Therapeutics Market, 2014-2024
6.9 The Chinese Prostate Cancer Therapeutics Market, 2014-2024
6.10 The South Korean Prostate Cancer Therapeutics Market, 2014-2024
6.11 The Mexican Prostate Cancer Therapeutics Market, 2014-2024
6.12 The Rest of the World Prostate Cancer Therapeutics Market, 2014-2024

7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2014-2024

7.1 SWOT Analysis, 2014-2024
7.2 Strengths
7.2.1 Prostate Cancer is a High Profile Disease
7.2.2 Rapidly Expanding Ageing Population
7.2.3 Targeted Therapies can Command Premium Prices
7.2.4 Strong R&D Pipeline
7.2.5 Successful Launches through Partnerships between Small/Big Pharma Companies
7.2.6 Use of Off-label Drugs is Common
7.3 Weaknesses
7.3.1 Prostate Cancer Drugs are Expensive
7.3.2 R&D Failures in Late-stage Development
7.3.3 Controversy Over the Value of New Prostate Cancer Devices
7.3.4 U.S Medical Excise Tax
7.4 Opportunities
7.4.1 Rising Incidence of cancer
7.4.2 Emerging National Markets will Drive Growth
7.4.3 Stem Cells Offer Promise
7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker
7.5 Threats
7.5.1 Concerns about Efficacy and Toxicity of Drugs
7.5.2 Who will Pay for the High Cost of Drugs and Devices?
7.5.3 Governments Decreasing Healthcare Spending
7.5.4 Increase in Generic Competition
7.5.5 Increase in the Practice of 'Active Surveillance'
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors [High]
7.6.2 Threat of New Entrants [High]
7.6.3 Power of Suppliers [Low]
7.6.4 Power of Buyers [High]
7.6.5 Threat of Substitutes [Low]

8. Expert Opinions

8.1 Professor Malcolm Mason, Cancer Research UK's Prostate Cancer Expert
8.1.1 Factors Affecting the Growth of Prostate Cancer
8.1.2 Prostate Cancer: To Treat or Not to Treat?
8.1.3 Alternatives to PSA Testing
8.1.4 A Common Option for Early Stage Prostate Cancer: Radical Prostatectomy
8.1.5 Large Number of Clinical Trials Studying Prostate Cancer
8.1.6 Combination Therapy: Better Survival Rates
8.1.7 Novel Prostate Cancer Drugs: A Question of Cost
8.2 Interview with Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
8.2.1 Tasquinimod: Phase III Pre-Chemotherapy Study
8.2.2 Tasquinimod: An Innovative Mode of Prostate Cancer Treatment
8.2.3 Active Biotech/Ipsen: Partnerships are Pivotal for Oncology Drug Development
8.2.4 Tasquinimod: Other Indications in the Pipeline
8.2.5 Competitive Landscape of the Prostate Cancer Drugs Market
8.2.6 The Drivers of Growth in the Prostate Market
8.3 Dr. Estuardo Aguilar-Cordova, Co-founder, CEO and Chairman, Advantagene
8.3.1 ProstAtak’s Mechanism for Prostate Cancer Prevention
8.3.2 ProsAtak’s Market Size
8.3.3 Immunotherapy: The Future for Cancer Treatment
8.3.4 Active Surveillance: A growing Trend

9. Conclusions

9.1 The Prostate Cancer Therapeutics Market, 2014-2024
9.2 The US Will Remain the Largest National Market from 2014 to 2024
9.3 Concluding Remarks

List of Tables

Table 2.1 PSA Testing: Benefits and Limitations, 2014
Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2014
Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m), Market Share (%) by Segment, 2013
Table 3.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 3.3The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2014-2024
Table 4.1 The Prostate Cancer Drugs List: Key Brands, 2014
Table 4.2 The Prostate Cancer Drugs Market: Revenue ($m), Market Share (%) by Leading
Drugs, 2013
Table 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 4.4 Market Shares (%) of the Leading Prostate Cancer Drugs, 2013, 2018 and 2024
Table 4.5 Sanofi: Taxotere Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.6 Sanofi: Jevtana Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.7 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.8 AbbVie: Lupron Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.9 AstraZeneca: Zoladex Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.10 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.11 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.12 Dendreon: Provenge Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.13 Bayer: Xofigo Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.14 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%), CAGR (%), 2013-2024
Table 4.15 Key Drugs in Phase III Clinical Trials, 2014
Table 4.16 Negative Phase III Clinical Trials, 2014
Table 4.17 Key Drugs in Phase II Clinical Trials, 2014
Table 4.18 Key Drugs in Phase I Clinical Trials, 2014
Table 4.19 Johnson & Johnson: Revenue ($bn) and Revenue Shares (%) by Segment, 2013
Table 4.20 Johnson & Johnson: Historical Revenue ($bn), AGR (%), CAGR (%), 2008-2013
Table 4.21 Johnson & Johnson Pharmaceuticals: Revenue ($bn), and Revenue Shares (%) by Segment, 2013
Table 4.22 Johnson & Johnson: Oncology Pharmaceuticals Segment: Revenue ($m) by Drug, 2011-2013
Table 4.23 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2013
Table 4.24 AstraZeneca: Revenue ($bn), AGR (%), CAGR (%), 2010-2013
Table 4.25 AstraZeneca: Revenue ($bn), Revenue Shares (%) by Segment, 2013
Table 4.26 AstraZeneca: Oncology Drugs Revenue ($m), Change in Revenue (%) and Revenue Shares (%), 2012-2013
Table 4.27 AstraZeneca: Oncology Phase II and III Pipeline, 2014
Table 4.28 Sanofi: Revenue ($bn), AGR (%), CAGR (%), 2009-2013
Table 4.29 Sanofi: Sale Revenue ($bn), Revenue Shares (%) by Segment, 2013
Table 4.30 Sanofi: Oncology Sales ($m) by Product, 2012-2013
Table 4.31 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2013
Table 4.32 Sanofi: Major Compounds from Sanofi’s Oncology Pipeline, 2014
Table 4.33 AbbVie: Revenue ($bn), AGR (%), CAGR (%), 2011-2013
Table 4.34 AbbVie: Revenue ($bn) by Drug, 2011-2013
Table 5.1 The Prostate Cancer Devices Market: Revenue ($m), Market Share (%) by Segment, 2013
Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2014-2024
Table 5.3 Market Shares (%) of the Leading Prostate Cancer Devices Submarkets, 2013, 2018 and 2024
Table 5.4 The Brachytherapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2024
Table 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%), CAGR (%),
2014-2024
Table 5.6 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%),
CAGR (%), 2014-2024
Table 5.7 The HIFU Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2024
Table 5.8 The Cryotherapy Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2024
Table 5.9 Varian Medical Systems: Revenue ($bn), AGR (%), CAGR (%), 2009-2013
Table 5.10 Varian Medical Systems: Revenue ($bn), Revenue Share (%) by Segment, 2013
Table 5.11 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Segment, 2013
Table 5.12 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as
Percentage of Revenue (%), 2011-2013
Table 5.13 Elekta: Revenue ($bn), AGR (%), CAGR (%) 2009-2013
Table 5.14 Elekta: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012
Table 5.15 Theragenics: Revenue ($m), AGR (%), CAGR (%) 2008-2012
Table 5.16 Theragenics: Revenue ($m), Revenue Share (%) by Business Unit, 2012
Table 6.1 The Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Region, 2013
Table 6.2 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%), CAGR(%), 2013-2024
Table 6.3 Market Shares (%) of the Leading Prostate Cancer Therapeutics National Markets,
2013, 2018 and 2024
Table 6.4 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),
CAGR (%), 2013-2024
Table 6.5 The European Prostate Cancer Therapeutics Markets: Revenue ($m), Market Share (%) by Country/Region, 2013
Table 6.6 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.7 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.8 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.9 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),
CAGR (%), 2013-2024
Table 6.10 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.11 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table6.12 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.13 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.14 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.15 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR(%), 2013-2024
Table 6.16 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.17 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.18 The Mexican Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 6.19 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2013-2024
Table 7.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2014-2024
Table 9.1 Market Share (%) of the Leading Regional Prostate Cancer Therapeutics Markets in 2013, 2018, 2024

List of Figures

Figure 1.2 Prostate Cancer Therapeutics: Overview of Submarkets and Segments
Figure 2.1 Global Proportion (%) of Newly diagnosed Cancer by Type (Excluding Non-Melanoma Skin Cancer), 2012
Figure 2.2 Treatment Sequence for Prostate Cancer, 2014
Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) by Segment, 2013
Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Share (%) by Segment,
2013
Figure 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($m) by Leading Drugs, 2013
Figure 4.2 The Prostate Cancer Drugs Market: Market Share (%) by Leading Drugs, 2013
Figure 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m), AGR (%), 2013-2024
Figure 4.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2018
Figure 4.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2024
Figure 4.6 Sanofi: Taxotere Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.7 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.8 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%),2013-2024
Figure 4.9 AbbVie: Lupron Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.10 AstraZeneca: Zoladex Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.11 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%),2013-2024
Figure 4.12 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%), 2013-2024
Figure 4.13 Dendreon: Provenge Revenue Forecast ($m), AGR (%) 2013-2024
Figure 4.14 Bayer: Xofigo Revenue Forecast ($m), AGR (%),2013-2024
Figure 4.15 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%), 2013-2024
Figure 4.16 Johnson & Johnson: Revenue Shares (%) by Segment, 2013
Figure 4.17 Johnson & Johnson: Historical Revenue ($bn),AGR (%), 2008-2013
Figure 4.18 Johnson & Johnson Pharmaceuticals: Revenue($bn) by Segment, 2013
Figure 4.19 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Segment, 2013
Figure 4.20 Johnson & Johnson Oncology Pharmaceuticals Segment: Market Share (%) by Drug, 2013
Figure 4.21 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D
Expenses as Percentage of Company Revenue (%), 2011-2013
Figure 4.22 AstraZeneca: Revenue ($bn), AGR (%), 2010-2013
Figure 4.23 AstraZeneca: Revenue ($bn) by Segment, 2013
Figure 4.24 AstraZeneca: Revenue Shares (%) by Segment, 2013
Figure 4.25 AstraZeneca: Oncology Drugs Revenue Share (%) by Brand Product, 2013
Figure 4.26 AstraZeneca: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2011-2013
Figure 4.27 Sanofi: Revenue ($bn), AGR (%), 2009-2013
Figure 4.28 Sanofi: Revenue ($bn) by Segment, 2013
Figure 4.29 Sanofi: Revenue Share (%) by Segment, 2013
Figure 4.30 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2013
Figure 4.31 AbbVie: Revenue ($bn), AGR (%),2011-2013
Figure 4.32 AbbVie: Revenue Share (%) by Drug, 2013
Figure 5.1 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2013
Figure 5.2 The Prostate Cancer Devices Market: Market Share (%) by Segment, 2013
Figure 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), 2014-2024
Figure 5.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Devices
Submarkets, 2018
Figure 5.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Devices
Submarkets, 2024
Figure 5.6 The Brachytherapy Market Forecast: Revenue ($m), AGR (%), 2014-2024
Figure 5.7 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%), 2014-2024
Figure 5.8 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%),
2014-2024
Figure 5.9 The HIFU Market Forecast: Revenue ($m),AGR (%), 2014-2024
Figure 5.10 The Cryotherapy Therapy Market Forecast: Revenue ($m), AGR (%), 2014-2024
Figure 5.11 Varian Medical Systems: Revenue ($bn), AGR (%), 2013-2024
Figure 5.12 Varian Medical Systems: Revenue ($bn) by Segment, 2013
Figure 5.13 Varian Medical Systems: Revenue Share (%) by Segment, 2013
Figure 5.14 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2013
Figure 5.15 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2013
Figure 5.16 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2013
Figure 5.17 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as
Percentage of Revenue (%), 2011-2013
Figure 5.18 Elekta: Historical Revenue ($bn), AGR (%), 2009-2013
Figure 5.19 Elekta: Revenue Share (%) by Region, 2012
Figure 5.20 Theragenics: Revenue ($m), AGR (%), 2008-2012
Figure 5.21 Theragenics: Revenue Share (%) by Operation, 2012
Figure 5.22 Theragenics: Revenue Share (%) by Business Unit, 2012
Figure 6.1 The Prostate Cancer Therapeutics Market: Revenue ($m) by Region, 2013
Figure 6.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2013
Figure 6.3 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2018
Figure 6.4 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2024
Figure 6.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR
(%), 2013-2024
Figure 6.6 The European Prostate Cancer Therapeutics Markets: Revenue ($m) by
Country/Region, 2013
Figure 6.7 The European Prostate Cancer Therapeutics Markets: Market Share (%) by
Country/Region, 2013
Figure 6.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.9 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.10 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.11 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR
(%), 2013-2024
Figure 6.12 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.13 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR
(%), 2013-2024
Figure 6.14 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.15 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.16 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.17 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.18 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.19 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.20 The Mexican Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 6.21 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2013-2024
Figure 7.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2013-2023
Figure 9.1 The Prostate Cancer Therapeutics Market: Revenues ($m) by Segment in 2013, 2018, 2024
Figure 9.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2024

掲載企業リスト

Companies Listed

AbbVie
Accord Healthcare
Actavis
Active Biotech
Advanced Medical Isotope Corporation
Advantagene
Agensys
Algeta
Aragon Pharmaceuticals (J&J)
Astellas
AstraZeneca
Bavarian Nordic
Bayer
Beckman Coulter (Danaher)
Bellicum Pharmaceuticals
Bostwick Laboratories
Bristol Myers Squibb
Computer Motion
Cougar Biotechnology
CP Medical
CR Bard
Dendreon
Elekta
EMD Serono
Exelixis
Firmagon
Galt Medical
GenomeDx Biosciences
Genomic Health
Gen-Probe (Hologic)
Hologic
Intuitive Surgical
Ipsen
Iris International (Danaher)
Janssen (J&J)
Johnson & Johnson
Juniper
Macrogenics
MDxHealth
Medivation
Merck
Merial (Sanofi)
Metabolon
Metamark Genetics
Millenium Pharmaceuticals
Mitomics
Mylan Pharmaceuticals
Myriad Genetics
Needle Tech Products
NorthWest Biotherapeutics
Nucletron
OncoGenex
Oncura
Opko Health
Philips
Progenics
Regeneron
Roche
Sandoz
Sanofi
Seattle Genetics
Siemens
Steba Biotech
Sun Pharmaceuticals
Sython Pharmaceuticals
Teva
Theragenics
Tokai
Varian Medical Systems
Xgeva
Zydus

Other Organisations Mentioned in this Report

Cedars-Sinai Medical Center
European Association of Urology
Levine Cancer Institute
Medical Research council (MRC)
Ministry of Health, Labour, and Welfare (MHLW) (Japanese)
National Cancer Institute
National Health Service (UK)
Prostate Cancer UK
The American Cancer Society
The American Society of Clinical Oncology (ASCO)
The Food and Drug Administration (FDA) (US)
The Froedtert & Medical College of Wisconsin Clinical Cancer Centre
The Italian National Health Service (INHS)
The National Institute of Clinical Excellence (NICE)
The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital (Netherlands)
The Sunnybrook Health Sciences (Ontario)
The University Medical Centre Utrecht (Netherlands)
The University of Adelaide
The University of California
The University of Cardiff
The University of Texas MD Anderson Centre (Texas)
The University of York
U.S. Center for Medicare and Medicaid Services (CMS)
UK National Cancer Research Network Prostate Cancer Clinical Studies Group
US Department of Defense
US Preventative Services Task Force (USPSTF)
World Cancer Research Fund International
World Health Organisation (WHO)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

関連レポート紹介

抗がん剤の世界市場2014-2024年:業界および研究開発動向

.当レポートでは抗がん剤の世界市場は2018年に1223億ドルに達し、2024年にかけて一層拡大していくと予測しています。

LinkIconレポート詳細ページへ

がん治療用キナーゼ阻害剤の世界市場2014-2024年

LinkIconレポート詳細ページへ

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。